Dominique Guerrot
@dguerrot.bsky.social
1K followers 510 following 52 posts
Nephrology, Hypertension, ADPKD, Clinical investigation | Rouen University Hospital, France
Posts Media Videos Starter Packs
Reposted by Dominique Guerrot
kidneyint.bsky.social
Mono-allelic pathogenic variants in JAG1 cause Autosomal Dominant Tubulo-interstitial Kidney Disease (ADTKD-JAG1)

doi.org/10.1016/j.kint.2025.08.033

#ckd #chronickidneydisease #MedSky #NephSky
@institutimagine.bsky.social @lafhf.bsky.social @nihrnewcastlebrc.bsky.social @ap-hp.bsky.social
Reposted by Dominique Guerrot
fperrywilson.bsky.social
Childhood obesity has quadrupled since the 1960s. Now over 20% of kids meet the definition (>95th percentile of BMI).
This is driving type 2 diabetes in children, and increases the risk of other diseases as adults.
We need to talk about weight-loss drugs for kids. 🧵
Reposted by Dominique Guerrot
pkdinternational.bsky.social
In this video, Professor Dominique Guerrot presents the DAPA-PKD study, a collaborative research effort he co-leads with Professor Emilie Cornec-Le Gall (Brest). This important study will evaluate the potential of SGLT2 inhibitors, such as dapagliflozin, in the treatment of #ADPKD.
Reposted by Dominique Guerrot
rnflex.bsky.social
I have a feeling sales of home blood pressure cuffs are going to spike because people working in Primary Care like myself are going to be telling patients to confirm what the Apple watch is telling them with an actual blood pressure cuff.
Reposted by Dominique Guerrot
labliston.bsky.social
🧵How to write and manage your first research budgets

The point of funding is to convert it into quality research. A well-spent research budget should fund the idea it was raised on, plus revision experiments, plus preliminary data for the next grant. So you need to spend, while avoiding waste.
Reposted by Dominique Guerrot
dguerrot.bsky.social
📚 The 2025 #KDIGO Guidelines recommend ambitious BP targets to manage hypertension in ADPKD:
🎯 ≤110/75 mmHg (HBPM) for adults <50 y with preserved renal function (G1–G2),
🎯 <120 mmHg systolic (office BP) in older adults, if tolerated.
dguerrot.bsky.social
#NephrOdio podcasts 🎧
🚀 Half a million downloads !
https://open.spotify.com/show/2UBeBVbxnfv8F9S82GENGa?si=JHcAmscnTPq3c25152duxw
Reposted by Dominique Guerrot
nejm.org
NEJM.org @nejm.org · Aug 13
CONFIDENCE trial: For patients with both chronic kidney disease and type 2 diabetes, whether combination therapy with finerenone and empagliflozin would improve outcomes over single-drug therapy is unclear. Research findings are summarized in a new Quick Take video. nej.md/40Szhuy
A visual representation of a patient with both chronic kidney disease and type 2 diabetes and finerenone + empagliflozin for treatment.
Reposted by Dominique Guerrot
hswapnil.medsky.social
In the introduction, @johngreensbluesky.bsky.social drops some TB facts

Annually more than a million people die of TB

Overall, more than a *billion* people have died of TB in last 2 centuries

That’s also something like 1 in 7 people who have ever lived 🤯

#NephJCBookClub
TB deaths from Our World in Data blob:https://ourworldindata.org/9c8bbafc-201d-482c-9f4c-17decf723a36
dguerrot.bsky.social
📖 To go deeper:
Review article by our team in Kidney International @theisn.org
👉 doi.org/10.1016/j.ki...
Redirecting
doi.org
dguerrot.bsky.social
🧠 Bottom line:
Controlling BP in ADPKD is not optional.
It’s essential for reducing risks to the heart, the brain (notably aneurysms), and probably the kidneys themselves.
dguerrot.bsky.social
💊 First-line treatment: RAAS blockade (#ACEi or #ARB).
Other drugs can be added depending on context:
• thiazide(-like) diuretics
• calcium channel blockers
• β-blockers
→ Adapted based on comorbidities, side effects, or tolvaptan use.
dguerrot.bsky.social
⚠️ These targets may be difficult to achieve or poorly tolerated in practice.
🧩 In such cases, the ESH (#EuropeanSocietyofHypertension) guideline target — <130/80 mmHg — may be a reasonable alternative, aiming for long-term adherence and safety. (Personal opinion)
dguerrot.bsky.social
📚 The 2025 #KDIGO Guidelines recommend ambitious BP targets to manage hypertension in ADPKD:
🎯 ≤110/75 mmHg (HBPM) for adults <50 y with preserved renal function (G1–G2),
🎯 <120 mmHg systolic (office BP) in older adults, if tolerated.
dguerrot.bsky.social
🔬 Before kidney function declines, 2 disease-specific mechanisms drive early #hypertension in #ADPKD:
📍 Local ischemia due to kidney #cyst expansion → RAAS activation
📍 Loss of polycystin function in blood vessels → primary #endothelial dysfunction
→ This sets ADPKD apart from other forms of CKD
dguerrot.bsky.social
🫀 #Hypertension in autosomal dominant polycystic kidney disease: unique pathways, common consequences.
In #ADPKD, high blood pressure is often the first clinical sign and not just a complication of the kidney disease.
Actually its mechanisms differ markedly from other CKD-related hypertension... 🧵
dguerrot.bsky.social
Interesting. Still surprising to me that nowadays nephrologists are not involved in kidney biopsy and dialysis catheter placement in some countries. Clearly reduces the interest of choosing the speciality IMO
Reposted by Dominique Guerrot
hswapnil.medsky.social
should we screen for CKD in the general population?

Finally, flozins, finerenone and GLP1s allow a good cost-effectiveness case

www.nephjc.com/news/2025/7/... for #NephJC shorts

Time to stop just being dialysis-ologists and flozinate, glipinate!

#NephSky
NephJC Shorts: Should we Screen for Kidney Disease? — NephJC
Should we screen for CKD?
www.nephjc.com
Reposted by Dominique Guerrot
alexchangmd.bsky.social
Awesome infographic on genetic testing in ADPKD by Neera Dahl, @pranavgarimella.bsky.social and Fouad Chebib www.kidneynews.org/view/journal...
Reposted by Dominique Guerrot